Core Viewpoint - The company, 荃信生物-B, has announced a share placement agreement to issue 5 million shares at a price of HKD 20.0 per share, which represents a discount of approximately 10.95% compared to the last trading price of HKD 22.46 on August 15, 2025 [1][2] Group 1 - The placement shares will account for approximately 2.25% of the existing shares as of the announcement date and about 2.20% of the expanded share capital after the placement [1] - The expected net proceeds from the placement, after deducting related costs, will be approximately HKD 99 million [2] - The company plans to allocate around 60% of the net proceeds to repay existing interest-bearing bank loans, which have increased due to additional borrowings for R&D expenses [2] Group 2 - Approximately 30% of the net proceeds will be used for the development of new pipelines, including QX027N, QX031N, and QX035N [2] - The remaining 10% of the net proceeds will be allocated for working capital and other corporate purposes [2]
荃信生物-B拟折让约10.95%配售500万股配售股份 净筹约9900万港元